Merck KGaA Keeps Powder Dry On Licensing Deals

Pleased With Potential Of Pipeline

After doing a number of healthcare deals in 2021, it looks as though Merck KGaA will keep M&A activity to a minimum for the division this year, focusing instead on advancing its own promising candidates for cancer, multiple sclerosis and lupus.

Garijo, Belen 1200
Belén Garijo • Source: Merck KGaA

Merck KGaA is taking a relaxed view to M&A and licensing activities in its healthcare segment, believing its existing portfolio and pipeline is enough to be focusing on for the time being.

So said CEO Belén Garijo when asked by Scrip whether the return to more rational valuations for biotechs meant that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business